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Abstract
Objective: The aim of this study was to examine the association between changes in blood oxidative stress level/
activity and changes in memory performance among postmenopausal women.
Methods: This study involved 39 postmenopausal women who received estrogen-progestin therapy (EPT) for
16 weeks. Verbal learning and memory performance were assessed using the Malay Version of Auditory Verbal
Learning Test before and after 16 weeks of EPT. Oxidative stress levels/activities before and after 16 weeks of EPT
were determined using commercially available kits. Data were analyzed using paired t test and r. P G 0.05 was
considered significant.
Results: The activities of glutathione peroxidase and catalase were considerably increased (P G 0.05), but the
level of 4-hydroxynonenal was notably decreased (P G 0.05), after 16 weeks of EPT. There were positive correla-
tions between changes in plasma superoxide dismutase and changes in trial A2 scores (r = 0.36, P G 0.05), and
between changes in the ratio of blood reduced glutathione to oxidized glutathione and changes in trial A2 scores (r =
0.34, P G 0.05).
Conclusions: Sixteen weeks of EPT increase blood antioxidant capacity. However, most of the changes in
oxidative stress level/activity are not significantly associated with changes in the memory performance of post-
menopausal women.
Key Words: Estrogen-progestin therapy Y Postmenopause Y Oxidative stress YMalay Version of Auditory Verbal
Learning Test.
T
he effect of hormone therapy (HT) on cognitive func-
tion remains inconclusive. Estrogen therapy has been
shown to reverse memory impairment associated with
estrogen deficiency and to lower the risk of developing dementia
in many studies involving postmenopausal women.1<13 In con-
trast, a number of studies found no protective effect of estrogen
on either cognitive functioning14<16 or dementia.17<19 Recently,
our group reported improvements in immediate memory,
immediate memory after interference, and delayed recall after
16 weeks of estrogen-progestin therapy (EPT) in postmenopausal
women.20
It has been suggested that cognitive impairment is a con-
sequence of imbalances between local reactive oxygen species
and antioxidant capacity within the brain21<23 and that an
unbalanced accumulation of oxidatively modified proteins in
the brain potentiates neurodegeneration and impairs cognitive
function.21,24 The relationship between cognition impairment
and oxidative stress is evident from the extensive damage
caused by free radicals in age-related neurological conditions
such as Alzheimer_s disease.25,26
Studies have shown that cognitive aging is significantly
related to variance in the blood levels of lipid peroxidation.27<31
The lipid peroxidation process has few end products, includ-
ing malondialdehyde, 4-hydroxynonenal (4-HNE), 4-hydroxy-
2-hexenal, and acrolein.32 4-HNE was found to be neurotoxic
and to inhibit enzymes critical for neuron survival, including
Na+/K+ ATPase, glucose, and glutamate transporters. 4-HNE
can lead to changes in the alteration process of neurofibrillary
tangles and has been shown to be involved in cognitive
impairment.33
There are many published studies on the effects of HT on
the status of oxidative stress in postmenopausal women,34<40
but little is known about its association with cognitive func-
tion. Recently, Ansari and Scheff41 reported an association
between oxidative stress levels and cognitive function in
postmortem brain samples. Therefore, the present study aims
to examine the association between changes in oxidative stress
level/activity and changes in memory performance in post-
menopausal women.
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METHODS
Procedure and design
The study protocol was approved by the Research and
Ethics Committee of Universiti Sains Malaysia. This study
involved 39 postmenopausal women aged between 45 and
60 years who had their final menstrual period more than 1 year
before study entry. The participants were recruited from the
Family Medicine and the Obstetrics and Gynecology Clinic,
Hospital Universiti Sains Malaysia. Participants were literate
and were not taking any form of medication that could alter
their memory function or any other herbal or hormone replace-
ment 3 months before the study. Participants were not chosen
if they smoked or had a history of drug or alcohol abuse or a
history of serious medical, surgical, mental, or gynecological
diseases. Participants underwent physical examinations, includ-
ing pelvic ultrasonography, to exclude endometrial thickness.
Postmenopausal women who fulfilled the criteria were
briefed on the nature of the study, and their consent to par-
ticipate was taken. During the initial visit, blood was obtained
to measure oxidative stress level/activity, and the participants’
verbal learning and memory performance were assessed. The
participants received Femoston Conti 1/5 (1 mg of 17A-estradiol
plus 5 mg of dydrogesterone) for 16 weeks. Health status,
compliance, and any possible adverse effects of EPT were
monitored at 8 weeks. After 16 weeks, oxidative stress status
and verbal learning and memory performance were reassessed.
Sample collection
Blood samples were collected into appropriate EDTA bot-
tles to determine oxidative stress level/activity. A total of
150 KL of whole blood was used to determine the ratio of
reduced glutathione (GSH) to oxidized glutathione (GSSG).
The remaining blood was centrifuged at 1,000g for 10 minutes
at 4-C to obtain plasma, aliquoted, and stored at j80-C until
assayed.
Determination of memory performance
Participants’ verbal learning and memory performance
were assessed using the Malay Version of Auditory Verbal
Learning Test (MVAVLT), as previously described.20,42 The
participants were asked to listen to 15 nouns (list A). List A
was read at a rate of one item per second (a tape recorder was
used to standardize the delivery rate). The participants had to
verbally repeat list A, and this trial was labeled as A1. The
procedures were repeated for another four times. In each trial,
the participants were asked to verbally repeat list A after each
presentation, and these trials were labeled as A2 to A5. The
second list (or list B) also contains 15 nouns presented to the
participants, and the participants were asked to verbally repeat
list B (B). A recall of list A was examined without prior pre-
sentation of the list by the examiner (A6). After 20 minutes of
rest, the recall of list A was repeated also without prior pre-
sentation (A7). Lastly, participants had to recognize the words
from list A, which were randomly interspersed among other
words in a list composed of 30 words.
Determination of blood oxidative stress level/activity
The blood GSH-to-GSSG ratio and the plasma catalase
(CAT), superoxide dismutase (SOD), and glutathione perox-
idase (GPx) activities were determined using a commercially
available kit (Calbiochem, Darmstadt, Germany). Plasma
4-HNE level was ascertained using the Oxiselect HNE-His
adduct ELISA kit (Cell Biolaboratories, San Diego, CA).
Procedures for the verification of antioxidant enzymes and
lipid oxidative damage were in accordance with the man-
ufacturer_s protocol. The intra-assay coefficients of variation
for GSH, GSSG, CAT, SOD, GPx, and 4-HNE were 0.96%,
6.45%, 5.7%, 5.9%, 5.6%, and 4.0%, respectively.
Statistical tests
Results were analyzed using PASW Statistics version 18.
Paired t test was used to examine differences in blood oxida-
tive stress values before and after 16 weeks of EPT. rwas used
to examine the association between changes in blood oxida-
tive stress level/activity and changes in memory performance.
P G 0.05 was considered statistically significant.
RESULTS
A total of 39 postmenopausal women participated in this
study, and the participants’ characteristics are summarized in
Table 1.
The mean MVAVLT scores before and after 16 weeks
of EPT were compared for each trial using paired t test, as
shown in Table 2. The mean scores for trials A1, A2, and A4
(immediate memory) were significantly increased when
comparing before and after EPT (P G 0.05). The mean scores
for total learning (summation of scores for trials A1-A5) were
TABLE 1. Characteristics of the participants
Age, mean (SEM), y 55.31 (0.49)
Menarche age, mean (SEM), y 13.87 (0.27)
Menopause age, mean (SEM), y 49.21 (0.79)
Duration of menopause, mean (SEM), y 6.28 (0.73)




TABLE 2. MVAVLT performance of the participants before and
after intervention
Trial Before intervention After intervention
A1 5.7 (0.3) 7.4 (0.3)a
A2 8.2 (0.4) 9.3 (0.3)a
A3 9.5 (0.3) 10.2 (0.3)
A4 10.1 (0.4) 11.3 (0.3)a
A5 11.1 (0.4) 11.6 (0.3)
Total learning 44.4 (1.3) 49.7 (1.2)a
B 5.0 (0.3) 5.7 (0.3)
A6 9.6 (0.4) 10.6 (0.3)a
A7 9.9 (0.4) 11.4 (0.3)a
Recognition 13.6 (0.3) 14.6 (0.1)a
Values are expressed as mean (SEM).
Preintervention and postintervention scores were compared using paired t test.
MVAVLT, Malay Version of Auditory Verbal Learning Test.
aP G 0.05 was considered statistically significant.
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significantly increased after EPT when compared with the
baseline value (P G 0.05). The mean scores for trial A6
(immediate memory after interference with list B), trial A7
(delayed memory), and recognition memory were also sig-
nificantly increased when contrasting before and after EPT
(P G 0.05). An untreated control group was included for the
assessment of memory performance to eliminate the possi-
bility of learning effects. Comparison between the untreated
control group and the EPT group showed a significant dif-
ference in mean MVAVLT scores for trial A1, trial A5, total
learning, trial A6, and trial A7. The complete results had been
published earlier.20
Blood estradiol and oxidative stress levels/activities meas-
ured before and after EPT in postmenopausal women are
summarized in Tables 3 and 4, respectively. The serum estradiol
levels of postmenopausal women were significantly increased
after 16 weeks of EPT (P G 0.05).
The plasma CAT and GPx activities were extensively
increased after 16 weeks of EPT (P G 0.05). The blood GSH-to-
GSSG ratio, an indicator of oxidative stress, was reduced but
was not statistically relevant. There seemed to be almost no
change in plasma SOD activity after EPT. Plasma 4-HNE lev-
els, however, showed considerable reduction after 16 weeks of
EPT (P G 0.05).
r revealed no significant association between the changes in
oxidative stress level/activity and the changes in trial scores,
except for the changes in trial A2 scores (immediate memory)
with changes in plasma SOD (r = 0.36, P G 0.05) and blood
GSH-to-GSSG ratio (r = 0.34, P G 0.05; Table 5).
DISCUSSION
The serum estradiol levels of postmenopausal women were
notably increased after 16 weeks of EPT. This finding sup-
ports the possibility of estrogen contributing to the memory
improvement observed in postmenopausal women treated
with EPT.20 It is believed that estrogen improves cognitive
function through its neuroprotective effects, and one of the
potential mechanisms involves the powerful antioxidant
properties of estrogen.43 Estrogen acts directly through its
phenolic hydroxyl group at the C3 position on the A ring of
steroid molecules44 and indirectly by increasing the levels of
endogenous antioxidant enzymes.45 17A-Estradiol has a
chemical structure that is quite comparable to the lipophilic
cellular antioxidant >-tocopherol (vitamin E). Both molecules
have a phenolic free radicalYscavenging group and a lip-
ophilic tail that mediates incorporation into membranes.
Similar to vitamin E, 17A-estradiol protects against oxidative
damage46 through direct quenching of reactive oxygen spe-
cies, leading to reduced oxidative stress.47
A significant increase in CAT activity occurred after
16 weeks of EPT. Increased CAT activity may indicate that
this enzyme operated continuously to decompose hydrogen
peroxide into harmless products. Recently, Ansari and Scheff 41
reported that CAT level was significantly decreased in the
postmortem brains of participants with mild cognitive impair-
ment and Alzheimer_s disease. Thus, it remains possible to
suggest that estrogen indirectly increases CAT enzyme activity
and improves memory performance in postmenopausal women
with EPT. Nevertheless, our findings were contradictory to the
findings of previous studies conducted in postmenopausal
women.35,38,39 Previous studies reported that CAT activity
displayed minute differences neither between treated and non-
treated postmenopausal women nor between premenopausal
and postmenopausal women.
GPx activity was significantly increased after 16 weeks
of EPT and was consistent with other studies.36,48 GPx
level significantly increased in postmenopausal women after
3 months (n = 22) and 6 months (n = 20) of therapy with
Premarin (0.625 mg/d for 25 d) and Provera (5 mg/d for
10 d).36 In another study, Massafra et al48 reported that
erythrocyte GPx was extensively higher in premenopausal
women (n = 90) than in postmenopausal women (n = 60).
Estrogen may exert antioxidant effects via the modulation
of intracellular GPx activity.49 However, our results are
inconsistent compared with those of previous studies that
found no difference in GPx activities in postmenopausal
women with and without HT38,50 and in the postmortem
brains of participants with mild cognitive impairment and
Alzheimer_s disease.41
The GSH-to-GSSG ratio represents the glutathione redox
status, an index of oxidative stress in all types of tissues, cells,
and organelles. Under normal physiological conditions, the
ratio is above 10.51 In this study, the GSH-to-GSSG ratio
was above the physiological level both before and after the
intervention. However, the ratio was found to be reduced
in postmenopausal women after 16 weeks of EPT. The GSH-
to-GSSG ratio will decrease as a consequence of GSSG
TABLE 3. Serum estradiol levels of the participants
Before intervention After intervention
Estradiol, mean (SEM), pmol/L 57.37 (12.08) 244.03 (48.12)a
Statistical comparisons before intervention and after intervention were per-
formed using paired t test.
aP G 0.05 was considered statistically significant.
TABLE 4. Blood oxidative stress level/activity of the participants
before and after intervention
Before intervention After intervention
Blood GSH-to-GSSG ratio 32.7 (8.0) 22.4 (6.9)
Plasma SOD, U/mL 0.068 (0.006) 0.069 (0.005)
Plasma CAT, nmol/min/mL 4.1 (0.4) 6.4 (0.5)a
Plasma GPx, nmol/min/mL 83.5 (5.7) 105.8 (8.3)a
Plasma 4-HNE, Kg/mL 3.4 (0.28) 2.6 (0.24)a
Values are expressed as mean (SEM).
Statistical comparisons before intervention and after intervention were per-
formed using paired t test.
GSH, reduced glutathione; GSSG, oxidized glutathione; SOD, superoxide
dismutase; CAT, catalase; GPx, glutathione peroxidase; 4-HNE, 4-hydroxynonenal.
aP G 0.05 was considered statistically significant.
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accumulation51,52 when exposed to increased oxidative stress.
Through EPT, depletion of GSH, together with evidence of
increased GPx, suggests an ongoing process to detoxify oxi-
dative stress. The present study revealed a significant positive
correlation between the changes in the blood GSH-to-GSSG
ratio and the changes in trial A2 scores. This finding implies
that when the oxidative stress level decreased (as shown by an
increased blood GSH-to-GSSG ratio), immediate memory
performance improved (as shown by increased trial A2
scores). This finding is supported by previous studies, which
revealed that older persons in urban areas had more oxidative
stress and a higher risk of developing cognitive impairment
when compared with older persons living in rural communities.53
The plasma SOD level was almost unchanged after 16 weeks
of EPT, but there was a significant positive correlation between
the changes in plasma SOD level and the changes in trial A2
scores. A study conducted by Ansari and Scheff 41 revealed that
the changes in antioxidant levels (ie, GSH, SOD, and CAT)
strongly correlated with the Mini Mental State Examination
score, supporting the idea that major changes in oxidative stress
compose an early event that plays an imperative role in the
progression of the disease. Our results are inconsistent, how-
ever, with those of previous studies, which showed either an
increase or a decrease in SOD levels with HT. Unfer et al39
showed an increase in SOD levels to premenopausal levels in
postmenopausal women treated with HT compared with post-
menopausal women without HT. Other studies, however,
showed a reduction in SOD levels after 6 months of HT.36
The present study revealed a reduction in plasma levels
of 4-HNE, a marker for lipid peroxidation, after 16 weeks
of EPT, consistent with the findings from a previous study.41
4-HNE has been shown to be associated with cognitive
impairment.33 It is consistent with our findings that a decrease
in plasma 4-HNE levels was related to improved memory
performance among postmenopausal women treated with EPT.
In the present study, the increase in the main antioxidant
enzyme activities reduces the production of hydrogen per-
oxide and reactive hydroxyl radicals and thus reduces oxida-
tive stress damage. The changes in peripheral antioxidant
activities may reflect similar changes in the brain regions
related to the memory function of postmenopausal women
treated with EPT. These findings may shed light on the pos-
sible neuroprotective roles of estrogen in memory function,
consistent with previous imaging studies. Positron emission
tomography studies indicate that HT modulates the pattern of
regional cerebral blood flow activation in brain regions that
play critical roles in memory processing and shows that
hypoperfusion occurs in individuals who are at an increased
risk of developing Alzheimer_s disease54<56 and who are in the
early stages of the disease.57 Shaywitz et al58 reported HT
effects on functional magnetic resonance imaging activation
patterns during the performance of verbal and visual working
memory tasks, similar to the findings in positron emission
tomography studies.
Limitations of the present study include the absence of an
age-matched control group for changes in blood oxidative
stress level/activity and the fact that the effects on blood oxi-
dative stress level/activity were not specified to different
stages of menopause. We were unable to control for certain
factors, such as diet, exercise, and health status, that were
known to alter oxidative stress level/activity and in turn may
exert direct or indirect effects on memory performance.
Therefore, in the present study, the baseline (before inter-
vention) values of the oxidative stress markers were used as
control values for each participant.
We suggest future causal relationship studies using a larger
sample size with age-matched controls and a longer duration
of EPT to confirm the association between the changes in
oxidative stress and the changes in the memory performance
of postmenopausal women at different stages of menopause.
CONCLUSIONS
Sixteen weeks of EPT reduce oxidative stress and improve
memory performance in postmenopausal women. It is unclear
whether the direct antioxidant properties of estrogen or its
indirect effects through increased plasma CAT and GPx
activities are capable of reducing oxidative stress. The asso-
ciation between the changes in the plasma level/activity of
oxidative stress and the changes in memory performance is
unremarkable. Only plasma SOD levels and the blood GSH-
to-GSSG ratio are positively correlated with the changes in
immediate memory performance.
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